×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RPRX – royalty pharma plc - class a ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RPRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/21
09:12 am
rprx
Teva, Medincell granted FDA review for long-acting antipsychotic [Seeking Alpha]
Low
Report
Teva, Medincell granted FDA review for long-acting antipsychotic [Seeking Alpha]
2/16
03:43 am
rprx
Royalty Pharma: 2025 Financial Performance And Strategic Outlook [Seeking Alpha]
Low
Report
Royalty Pharma: 2025 Financial Performance And Strategic Outlook [Seeking Alpha]
2/15
08:02 am
rprx
Royalty Pharma plc (NASDAQ:RPRX) Passed Our Checks, And It's About To Pay A US$0.235 Dividend [Yahoo! Finance]
Low
Report
Royalty Pharma plc (NASDAQ:RPRX) Passed Our Checks, And It's About To Pay A US$0.235 Dividend [Yahoo! Finance]
2/13
06:33 pm
rprx
Royalty Pharma (NASDAQ:RPRX) was upgraded by analysts at Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
Low
Report
Royalty Pharma (NASDAQ:RPRX) was upgraded by analysts at Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
2/12
12:21 pm
rprx
Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View [Seeking Alpha]
Low
Report
Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View [Seeking Alpha]
2/12
10:07 am
rprx
Royalty Pharma (NASDAQ:RPRX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Royalty Pharma (NASDAQ:RPRX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
2/12
09:06 am
rprx
Royalty Pharma (NASDAQ:RPRX) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Royalty Pharma (NASDAQ:RPRX) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
2/11
04:48 pm
rprx
Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/23
05:07 pm
rprx
Form 144 Royalty Pharma plc Filed by: Coyne Terrance P.
Low
Report
Form 144 Royalty Pharma plc Filed by: Coyne Terrance P.
2/20
04:28 pm
rprx
Form SCHEDULE 13D/A Royalty Pharma plc Filed by: Severgnini Achille G.
Low
Report
Form SCHEDULE 13D/A Royalty Pharma plc Filed by: Severgnini Achille G.
2/13
04:30 pm
rprx
Form SCHEDULE 13G/A Royalty Pharma plc Filed by: Capital International Investors
Low
Report
Form SCHEDULE 13G/A Royalty Pharma plc Filed by: Capital International Investors
2/13
04:04 pm
rprx
Form 4 Royalty Pharma plc For: Feb 11 Filed by: Legorreta Pablo G.
Low
Report
Form 4 Royalty Pharma plc For: Feb 11 Filed by: Legorreta Pablo G.
2/13
04:03 pm
rprx
Form 4 Royalty Pharma plc For: Feb 11 Filed by: Urist Marshall
Low
Report
Form 4 Royalty Pharma plc For: Feb 11 Filed by: Urist Marshall
2/13
04:03 pm
rprx
Form 4 Royalty Pharma plc For: Feb 11 Filed by: Coyne Terrance P.
Low
Report
Form 4 Royalty Pharma plc For: Feb 11 Filed by: Coyne Terrance P.
2/13
04:03 pm
rprx
Form 4 Royalty Pharma plc For: Feb 11 Filed by: Hite Christopher
Low
Report
Form 4 Royalty Pharma plc For: Feb 11 Filed by: Hite Christopher
2/11
09:04 am
rprx
Form 10-K Royalty Pharma plc For: Dec 31
Low
Report
Form 10-K Royalty Pharma plc For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/12
Repros Therapeutics Inc.® Announces Acquisition by Allergan plc
49.1%
12/15 Prospects dim for European approval of Repros' enclomiphene for secondary hypogonadism; shares down 10% after hours [Seeking Alpha] 7.0%
1/4 Form SC TO-T/A REPROS THERAPEUTICS INC. Filed by: Allergan plc 5.3%
1/30 Form SC TO-T/A REPROS THERAPEUTICS INC. Filed by: Allergan plc 2.3%
12/21 Biotech Stocks' Research Reports Released on Repros Therapeutics, Aldeyra Therapeutics, Neothetics, and BioLine Rx 2.0%
12/29 Form SC TO-T REPROS THERAPEUTICS INC. Filed by: Allergan plc 0.9%
12/14 Biotech Analysis Central Pharma News: AbbVie And Roche Stellar Data, Aduro Pulls The Cord, Allergan's Bargain Bin Buy [Seeking Alpha] 0.3%
1/19 Form SC 14D9/A REPROS THERAPEUTICS INC. Filed by: REPROS THERAPEUTICS INC. 0.2%
1/9 Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Repros Therapeutics Inc. In The Southern District Of Texas Houston Division 0.1%
12/12 REPROS THERAPEUTICS INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout 0.0%
12/15 Prospects dim for European approval of Repros' enclomiphene for secondary hypogonadism; shares down 10% after hours [Seeking Alpha] 7.0%
1/4 Form SC TO-T/A REPROS THERAPEUTICS INC. Filed by: Allergan plc 5.3%
1/30 Form SC TO-T/A REPROS THERAPEUTICS INC. Filed by: Allergan plc 2.3%
12/21 Biotech Stocks' Research Reports Released on Repros Therapeutics, Aldeyra Therapeutics, Neothetics, and BioLine Rx 2.0%
12/29 Form SC TO-T REPROS THERAPEUTICS INC. Filed by: Allergan plc 0.9%
12/14 Biotech Analysis Central Pharma News: AbbVie And Roche Stellar Data, Aduro Pulls The Cord, Allergan's Bargain Bin Buy [Seeking Alpha] 0.3%
1/19 Form SC 14D9/A REPROS THERAPEUTICS INC. Filed by: REPROS THERAPEUTICS INC. 0.2%
1/9 Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Repros Therapeutics Inc. In The Southern District Of Texas Houston Division 0.1%
12/12 REPROS THERAPEUTICS INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout 0.0%
TOP News Decliners
1/31
Form POS AM REPROS THERAPEUTICS INC.
-6.9%
12/15 Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency -5.6%
11/20 Repros Therapeutics Inc. (NASDAQ: RPRX) had its price target lowered by analysts at S&P Equity Research from $0.49 to $0.39. -3.4%
1/26 BRIEF-Repros Announces Negative Opinion From The EMA For Enclomiphene [Reuters] -1.3%
12/12 Form 8-K REPROS THERAPEUTICS INC. For: Dec 11 -0.8%
12/29 Form SC 14D9 REPROS THERAPEUTICS INC. Filed by: REPROS THERAPEUTICS INC. -0.5%
1/2 BRIEF-MMCAP International Reports An 8.48 Pct Passive Stake In Repros Therapeutics [Reuters] -0.3%
12/13 Form SC14D9C REPROS THERAPEUTICS INC. Filed by: REPROS THERAPEUTICS INC. -0.2%
1/26 European advisory group backs seven medicines for approval, rejects Repros' enclomiphene [Seeking Alpha] -0.1%
1/5 Form SC TO-T/A REPROS THERAPEUTICS INC. Filed by: Allergan plc -0.1%
12/15 Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency -5.6%
11/20 Repros Therapeutics Inc. (NASDAQ: RPRX) had its price target lowered by analysts at S&P Equity Research from $0.49 to $0.39. -3.4%
1/26 BRIEF-Repros Announces Negative Opinion From The EMA For Enclomiphene [Reuters] -1.3%
12/12 Form 8-K REPROS THERAPEUTICS INC. For: Dec 11 -0.8%
12/29 Form SC 14D9 REPROS THERAPEUTICS INC. Filed by: REPROS THERAPEUTICS INC. -0.5%
1/2 BRIEF-MMCAP International Reports An 8.48 Pct Passive Stake In Repros Therapeutics [Reuters] -0.3%
12/13 Form SC14D9C REPROS THERAPEUTICS INC. Filed by: REPROS THERAPEUTICS INC. -0.2%
1/26 European advisory group backs seven medicines for approval, rejects Repros' enclomiphene [Seeking Alpha] -0.1%
1/5 Form SC TO-T/A REPROS THERAPEUTICS INC. Filed by: Allergan plc -0.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: